nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—CYP3A7—Vincristine—sarcoma	0.0926	0.12	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0926	0.12	CbGbCtD
Norethindrone—CYP3A4—Thiotepa—sarcoma	0.0915	0.119	CbGbCtD
Norethindrone—ABCB1—Dactinomycin—sarcoma	0.0734	0.0951	CbGbCtD
Norethindrone—CYP3A5—Vincristine—sarcoma	0.0694	0.09	CbGbCtD
Norethindrone—ABCB1—Mitoxantrone—sarcoma	0.0657	0.0851	CbGbCtD
Norethindrone—CYP3A5—Etoposide—sarcoma	0.0636	0.0824	CbGbCtD
Norethindrone—ABCB1—Vincristine—sarcoma	0.0452	0.0585	CbGbCtD
Norethindrone—ABCB1—Etoposide—sarcoma	0.0414	0.0537	CbGbCtD
Norethindrone—CYP3A4—Mitoxantrone—sarcoma	0.0393	0.051	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—sarcoma	0.0282	0.0366	CbGbCtD
Norethindrone—CYP3A4—Vincristine—sarcoma	0.0271	0.0351	CbGbCtD
Norethindrone—CYP3A4—Etoposide—sarcoma	0.0248	0.0321	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—sarcoma	0.0169	0.0219	CbGbCtD
Norethindrone—SHBG—hindlimb—sarcoma	0.00306	0.162	CbGeAlD
Norethindrone—Vaginal haemorrhage—Thiotepa—sarcoma	0.00286	0.0137	CcSEcCtD
Norethindrone—Abdominal cramps—Vincristine—sarcoma	0.00278	0.0133	CcSEcCtD
Norethindrone—Menorrhagia—Vincristine—sarcoma	0.00254	0.0121	CcSEcCtD
Norethindrone—Neoplasm malignant—Thiotepa—sarcoma	0.00248	0.0119	CcSEcCtD
Norethindrone—Optic neuritis—Etoposide—sarcoma	0.00248	0.0118	CcSEcCtD
Norethindrone—Menorrhagia—Mitoxantrone—sarcoma	0.00247	0.0118	CcSEcCtD
Norethindrone—Amenorrhoea—Thiotepa—sarcoma	0.00241	0.0115	CcSEcCtD
Norethindrone—Amenorrhoea—Mitoxantrone—sarcoma	0.00208	0.00995	CcSEcCtD
Norethindrone—Erythema nodosum—Epirubicin—sarcoma	0.00197	0.00943	CcSEcCtD
Norethindrone—Erythema nodosum—Doxorubicin—sarcoma	0.00183	0.00872	CcSEcCtD
Norethindrone—Blindness—Epirubicin—sarcoma	0.00154	0.00736	CcSEcCtD
Norethindrone—Blindness—Doxorubicin—sarcoma	0.00143	0.00681	CcSEcCtD
Norethindrone—Optic neuritis—Epirubicin—sarcoma	0.00139	0.00663	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Mitoxantrone—sarcoma	0.00137	0.00656	CcSEcCtD
Norethindrone—Pain in extremity—Vincristine—sarcoma	0.00136	0.00652	CcSEcCtD
Norethindrone—Embolism—Epirubicin—sarcoma	0.00133	0.00635	CcSEcCtD
Norethindrone—Optic neuritis—Doxorubicin—sarcoma	0.00128	0.00613	CcSEcCtD
Norethindrone—Embolism—Doxorubicin—sarcoma	0.00123	0.00588	CcSEcCtD
Norethindrone—Weight increased—Thiotepa—sarcoma	0.00121	0.00578	CcSEcCtD
Norethindrone—Thrombosis—Epirubicin—sarcoma	0.00121	0.00576	CcSEcCtD
Norethindrone—Renal failure—Thiotepa—sarcoma	0.00117	0.00557	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Epirubicin—sarcoma	0.00115	0.00551	CcSEcCtD
Norethindrone—Dermatitis atopic—Epirubicin—sarcoma	0.00115	0.00551	CcSEcCtD
Norethindrone—PGR—mammary gland—sarcoma	0.00115	0.0611	CbGeAlD
Norethindrone—Anaphylactoid reaction—Etoposide—sarcoma	0.00114	0.00546	CcSEcCtD
Norethindrone—Hepatobiliary disease—Thiotepa—sarcoma	0.00112	0.00536	CcSEcCtD
Norethindrone—Thrombosis—Doxorubicin—sarcoma	0.00112	0.00533	CcSEcCtD
Norethindrone—Photosensitivity reaction—Vincristine—sarcoma	0.00108	0.00514	CcSEcCtD
Norethindrone—Haemoglobin—Thiotepa—sarcoma	0.00107	0.00511	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Doxorubicin—sarcoma	0.00107	0.0051	CcSEcCtD
Norethindrone—Dermatitis atopic—Doxorubicin—sarcoma	0.00107	0.0051	CcSEcCtD
Norethindrone—Haemorrhage—Thiotepa—sarcoma	0.00106	0.00509	CcSEcCtD
Norethindrone—Hepatitis—Dactinomycin—sarcoma	0.00106	0.00505	CcSEcCtD
Norethindrone—ALB—mammary gland—sarcoma	0.00106	0.056	CbGeAlD
Norethindrone—Depression—Vincristine—sarcoma	0.00105	0.00501	CcSEcCtD
Norethindrone—Connective tissue disorder—Thiotepa—sarcoma	0.00105	0.005	CcSEcCtD
Norethindrone—Weight increased—Mitoxantrone—sarcoma	0.00105	0.00499	CcSEcCtD
Norethindrone—Acute coronary syndrome—Vincristine—sarcoma	0.00104	0.00495	CcSEcCtD
Norethindrone—Myocardial infarction—Vincristine—sarcoma	0.00103	0.00492	CcSEcCtD
Norethindrone—Drowsiness—Mitoxantrone—sarcoma	0.00102	0.00489	CcSEcCtD
Norethindrone—Acute coronary syndrome—Mitoxantrone—sarcoma	0.00101	0.00482	CcSEcCtD
Norethindrone—Renal failure—Mitoxantrone—sarcoma	0.00101	0.00481	CcSEcCtD
Norethindrone—Myocardial infarction—Mitoxantrone—sarcoma	0.001	0.0048	CcSEcCtD
Norethindrone—Neoplasm malignant—Epirubicin—sarcoma	0.000999	0.00478	CcSEcCtD
Norethindrone—Erythema multiforme—Dactinomycin—sarcoma	0.000999	0.00477	CcSEcCtD
Norethindrone—Breast pain—Epirubicin—sarcoma	0.000978	0.00467	CcSEcCtD
Norethindrone—Jaundice cholestatic—Epirubicin—sarcoma	0.000971	0.00464	CcSEcCtD
Norethindrone—Amenorrhoea—Epirubicin—sarcoma	0.000971	0.00464	CcSEcCtD
Norethindrone—Immune system disorder—Thiotepa—sarcoma	0.000961	0.00459	CcSEcCtD
Norethindrone—Alopecia—Thiotepa—sarcoma	0.000941	0.00449	CcSEcCtD
Norethindrone—Alopecia—Dactinomycin—sarcoma	0.000933	0.00446	CcSEcCtD
Norethindrone—Mental disorder—Thiotepa—sarcoma	0.000932	0.00446	CcSEcCtD
Norethindrone—Connective tissue disorder—Vincristine—sarcoma	0.000927	0.00443	CcSEcCtD
Norethindrone—Neoplasm malignant—Doxorubicin—sarcoma	0.000925	0.00442	CcSEcCtD
Norethindrone—Haemoglobin—Mitoxantrone—sarcoma	0.000924	0.00441	CcSEcCtD
Norethindrone—Haemorrhage—Mitoxantrone—sarcoma	0.000919	0.00439	CcSEcCtD
Norethindrone—Hepatitis—Mitoxantrone—sarcoma	0.000919	0.00439	CcSEcCtD
Norethindrone—Tension—Thiotepa—sarcoma	0.000909	0.00434	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—sarcoma	0.000905	0.00432	CcSEcCtD
Norethindrone—Nervousness—Thiotepa—sarcoma	0.0009	0.0043	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—sarcoma	0.000899	0.00429	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—sarcoma	0.000899	0.00429	CcSEcCtD
Norethindrone—Pulmonary embolism—Epirubicin—sarcoma	0.000853	0.00408	CcSEcCtD
Norethindrone—Acute coronary syndrome—Etoposide—sarcoma	0.00084	0.00401	CcSEcCtD
Norethindrone—Renal failure—Etoposide—sarcoma	0.000837	0.004	CcSEcCtD
Norethindrone—Myocardial infarction—Etoposide—sarcoma	0.000835	0.00399	CcSEcCtD
Norethindrone—Alopecia—Vincristine—sarcoma	0.000834	0.00398	CcSEcCtD
Norethindrone—Mental disorder—Vincristine—sarcoma	0.000827	0.00395	CcSEcCtD
Norethindrone—PGR—myometrium—sarcoma	0.000817	0.0433	CbGeAlD
Norethindrone—Alopecia—Mitoxantrone—sarcoma	0.000812	0.00388	CcSEcCtD
Norethindrone—Hepatobiliary disease—Etoposide—sarcoma	0.000805	0.00385	CcSEcCtD
Norethindrone—Convulsion—Thiotepa—sarcoma	0.000803	0.00384	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—sarcoma	0.00079	0.00377	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000783	0.00374	CcSEcCtD
Norethindrone—SHBG—hematopoietic system—sarcoma	0.000779	0.0413	CbGeAlD
Norethindrone—Oedema—Dactinomycin—sarcoma	0.00075	0.00359	CcSEcCtD
Norethindrone—SHBG—connective tissue—sarcoma	0.00075	0.0398	CbGeAlD
Norethindrone—Skin disorder—Thiotepa—sarcoma	0.000734	0.00351	CcSEcCtD
Norethindrone—Erythema multiforme—Etoposide—sarcoma	0.000723	0.00345	CcSEcCtD
Norethindrone—Thrombophlebitis—Epirubicin—sarcoma	0.000716	0.00342	CcSEcCtD
Norethindrone—Convulsion—Vincristine—sarcoma	0.000712	0.0034	CcSEcCtD
Norethindrone—Photosensitivity—Epirubicin—sarcoma	0.000706	0.00337	CcSEcCtD
Norethindrone—PGR—hematopoietic system—sarcoma	0.000702	0.0372	CbGeAlD
Norethindrone—Convulsion—Mitoxantrone—sarcoma	0.000693	0.00331	CcSEcCtD
Norethindrone—Immune system disorder—Etoposide—sarcoma	0.000691	0.0033	CcSEcCtD
Norethindrone—PGR—connective tissue—sarcoma	0.000676	0.0358	CbGeAlD
Norethindrone—Alopecia—Etoposide—sarcoma	0.000676	0.00323	CcSEcCtD
Norethindrone—Somnolence—Thiotepa—sarcoma	0.000672	0.00321	CcSEcCtD
Norethindrone—Oedema—Vincristine—sarcoma	0.000671	0.0032	CcSEcCtD
Norethindrone—Anaphylactic shock—Vincristine—sarcoma	0.000671	0.0032	CcSEcCtD
Norethindrone—Dyspepsia—Thiotepa—sarcoma	0.000666	0.00318	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—sarcoma	0.000662	0.00316	CcSEcCtD
Norethindrone—Anaphylactic shock—Mitoxantrone—sarcoma	0.000653	0.00312	CcSEcCtD
Norethindrone—Oedema—Mitoxantrone—sarcoma	0.000653	0.00312	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Thiotepa—sarcoma	0.000653	0.00312	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—sarcoma	0.000653	0.00312	CcSEcCtD
Norethindrone—Fatigue—Thiotepa—sarcoma	0.000652	0.00311	CcSEcCtD
Norethindrone—Renal impairment—Epirubicin—sarcoma	0.000651	0.00311	CcSEcCtD
Norethindrone—Fatigue—Dactinomycin—sarcoma	0.000647	0.00309	CcSEcCtD
Norethindrone—Purpura—Epirubicin—sarcoma	0.000643	0.00307	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—sarcoma	0.00064	0.00306	CcSEcCtD
Norethindrone—Skin disorder—Mitoxantrone—sarcoma	0.000634	0.00303	CcSEcCtD
Norethindrone—Pain in extremity—Epirubicin—sarcoma	0.000619	0.00296	CcSEcCtD
Norethindrone—Gastrointestinal pain—Thiotepa—sarcoma	0.000618	0.00295	CcSEcCtD
Norethindrone—PGR—smooth muscle tissue—sarcoma	0.000618	0.0328	CbGeAlD
Norethindrone—Gastrointestinal pain—Dactinomycin—sarcoma	0.000614	0.00293	CcSEcCtD
Norethindrone—Migraine—Epirubicin—sarcoma	0.00061	0.00291	CcSEcCtD
Norethindrone—Affect lability—Epirubicin—sarcoma	0.00061	0.00291	CcSEcCtD
Norethindrone—Insomnia—Vincristine—sarcoma	0.000606	0.0029	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—sarcoma	0.000602	0.00288	CcSEcCtD
Norethindrone—CYP3A7—liver—sarcoma	0.000601	0.0319	CbGeAlD
Norethindrone—Urticaria—Thiotepa—sarcoma	0.000601	0.00287	CcSEcCtD
Norethindrone—Abdominal pain—Thiotepa—sarcoma	0.000598	0.00286	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—sarcoma	0.000595	0.00284	CcSEcCtD
Norethindrone—Abdominal pain—Dactinomycin—sarcoma	0.000593	0.00283	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000592	0.00283	CcSEcCtD
Norethindrone—SHBG—uterus—sarcoma	0.000589	0.0312	CbGeAlD
Norethindrone—Mood swings—Epirubicin—sarcoma	0.000587	0.0028	CcSEcCtD
Norethindrone—Somnolence—Mitoxantrone—sarcoma	0.000581	0.00277	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Vincristine—sarcoma	0.000579	0.00277	CcSEcCtD
Norethindrone—Fatigue—Vincristine—sarcoma	0.000578	0.00276	CcSEcCtD
Norethindrone—Convulsion—Etoposide—sarcoma	0.000577	0.00276	CcSEcCtD
Norethindrone—Dyspepsia—Mitoxantrone—sarcoma	0.000575	0.00275	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—sarcoma	0.000573	0.00274	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—sarcoma	0.000564	0.0027	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—sarcoma	0.000564	0.0027	CcSEcCtD
Norethindrone—Fatigue—Mitoxantrone—sarcoma	0.000563	0.00269	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000563	0.00269	CcSEcCtD
Norethindrone—Breast disorder—Epirubicin—sarcoma	0.00056	0.00267	CcSEcCtD
Norethindrone—Hypersensitivity—Thiotepa—sarcoma	0.000557	0.00266	CcSEcCtD
Norethindrone—Hypersensitivity—Dactinomycin—sarcoma	0.000553	0.00264	CcSEcCtD
Norethindrone—Gastrointestinal pain—Vincristine—sarcoma	0.000548	0.00262	CcSEcCtD
Norethindrone—Anaphylactic shock—Etoposide—sarcoma	0.000543	0.0026	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—sarcoma	0.000543	0.00259	CcSEcCtD
Norethindrone—Asthenia—Thiotepa—sarcoma	0.000543	0.00259	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—sarcoma	0.000539	0.00258	CcSEcCtD
Norethindrone—Asthenia—Dactinomycin—sarcoma	0.000538	0.00257	CcSEcCtD
Norethindrone—Pruritus—Thiotepa—sarcoma	0.000535	0.00256	CcSEcCtD
Norethindrone—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000534	0.00255	CcSEcCtD
Norethindrone—PGR—uterus—sarcoma	0.00053	0.0281	CbGeAlD
Norethindrone—Abdominal pain—Vincristine—sarcoma	0.00053	0.00253	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—sarcoma	0.000528	0.00252	CcSEcCtD
Norethindrone—Urticaria—Mitoxantrone—sarcoma	0.000519	0.00248	CcSEcCtD
Norethindrone—CYP2C19—hematopoietic system—sarcoma	0.000518	0.0275	CbGeAlD
Norethindrone—Breast disorder—Doxorubicin—sarcoma	0.000518	0.00247	CcSEcCtD
Norethindrone—Abdominal pain—Mitoxantrone—sarcoma	0.000516	0.00247	CcSEcCtD
Norethindrone—CYP3A7-CYP3A51P—liver—sarcoma	0.000511	0.0271	CbGeAlD
Norethindrone—Dizziness—Thiotepa—sarcoma	0.0005	0.00239	CcSEcCtD
Norethindrone—SHBG—bone marrow—sarcoma	0.000499	0.0265	CbGeAlD
Norethindrone—Abdominal distension—Doxorubicin—sarcoma	0.000499	0.00238	CcSEcCtD
Norethindrone—PGR—lymphoid tissue—sarcoma	0.000494	0.0262	CbGeAlD
Norethindrone—Hypersensitivity—Vincristine—sarcoma	0.000494	0.00236	CcSEcCtD
Norethindrone—Photosensitivity reaction—Epirubicin—sarcoma	0.000489	0.00234	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—sarcoma	0.000487	0.00233	CcSEcCtD
Norethindrone—Somnolence—Etoposide—sarcoma	0.000483	0.00231	CcSEcCtD
Norethindrone—Hypersensitivity—Mitoxantrone—sarcoma	0.000481	0.0023	CcSEcCtD
Norethindrone—Asthenia—Vincristine—sarcoma	0.000481	0.0023	CcSEcCtD
Norethindrone—Vomiting—Thiotepa—sarcoma	0.000481	0.0023	CcSEcCtD
Norethindrone—Drowsiness—Epirubicin—sarcoma	0.000477	0.00228	CcSEcCtD
Norethindrone—Vomiting—Dactinomycin—sarcoma	0.000477	0.00228	CcSEcCtD
Norethindrone—Rash—Thiotepa—sarcoma	0.000477	0.00228	CcSEcCtD
Norethindrone—Dermatitis—Thiotepa—sarcoma	0.000476	0.00228	CcSEcCtD
Norethindrone—Headache—Thiotepa—sarcoma	0.000474	0.00226	CcSEcCtD
Norethindrone—Rash—Dactinomycin—sarcoma	0.000473	0.00226	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—sarcoma	0.000469	0.00224	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Etoposide—sarcoma	0.000469	0.00224	CcSEcCtD
Norethindrone—Asthenia—Mitoxantrone—sarcoma	0.000469	0.00224	CcSEcCtD
Norethindrone—Fatigue—Etoposide—sarcoma	0.000468	0.00224	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—sarcoma	0.000452	0.00216	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—sarcoma	0.000451	0.00216	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—sarcoma	0.000451	0.00215	CcSEcCtD
Norethindrone—Nausea—Thiotepa—sarcoma	0.000449	0.00215	CcSEcCtD
Norethindrone—Nausea—Dactinomycin—sarcoma	0.000446	0.00213	CcSEcCtD
Norethindrone—Gastrointestinal pain—Etoposide—sarcoma	0.000444	0.00212	CcSEcCtD
Norethindrone—Dizziness—Vincristine—sarcoma	0.000443	0.00212	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—sarcoma	0.000442	0.00211	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—sarcoma	0.000434	0.00207	CcSEcCtD
Norethindrone—Urticaria—Etoposide—sarcoma	0.000432	0.00206	CcSEcCtD
Norethindrone—Haemoglobin—Epirubicin—sarcoma	0.000431	0.00206	CcSEcCtD
Norethindrone—Abdominal pain—Etoposide—sarcoma	0.000429	0.00205	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—sarcoma	0.000429	0.00205	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—sarcoma	0.000429	0.00205	CcSEcCtD
Norethindrone—SHBG—testis—sarcoma	0.000427	0.0226	CbGeAlD
Norethindrone—Vomiting—Vincristine—sarcoma	0.000426	0.00204	CcSEcCtD
Norethindrone—Rash—Vincristine—sarcoma	0.000423	0.00202	CcSEcCtD
Norethindrone—Dermatitis—Vincristine—sarcoma	0.000422	0.00202	CcSEcCtD
Norethindrone—Connective tissue disorder—Epirubicin—sarcoma	0.000421	0.00201	CcSEcCtD
Norethindrone—Headache—Vincristine—sarcoma	0.00042	0.00201	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—sarcoma	0.000418	0.002	CcSEcCtD
Norethindrone—Vomiting—Mitoxantrone—sarcoma	0.000415	0.00198	CcSEcCtD
Norethindrone—Rash—Mitoxantrone—sarcoma	0.000412	0.00197	CcSEcCtD
Norethindrone—Dermatitis—Mitoxantrone—sarcoma	0.000411	0.00197	CcSEcCtD
Norethindrone—Headache—Mitoxantrone—sarcoma	0.000409	0.00195	CcSEcCtD
Norethindrone—CYP3A5—hematopoietic system—sarcoma	0.000408	0.0216	CbGeAlD
Norethindrone—Erythema multiforme—Epirubicin—sarcoma	0.000405	0.00194	CcSEcCtD
Norethindrone—SHBG—liver—sarcoma	0.000404	0.0214	CbGeAlD
Norethindrone—Hypersensitivity—Etoposide—sarcoma	0.0004	0.00191	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—sarcoma	0.000399	0.0019	CcSEcCtD
Norethindrone—Nausea—Vincristine—sarcoma	0.000398	0.0019	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—sarcoma	0.000397	0.00189	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—sarcoma	0.000397	0.00189	CcSEcCtD
Norethindrone—Asthenia—Etoposide—sarcoma	0.00039	0.00186	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—sarcoma	0.00039	0.00186	CcSEcCtD
Norethindrone—Nausea—Mitoxantrone—sarcoma	0.000388	0.00185	CcSEcCtD
Norethindrone—Immune system disorder—Epirubicin—sarcoma	0.000387	0.00185	CcSEcCtD
Norethindrone—PGR—testis—sarcoma	0.000385	0.0204	CbGeAlD
Norethindrone—Pruritus—Etoposide—sarcoma	0.000384	0.00184	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—sarcoma	0.000379	0.00181	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—sarcoma	0.000375	0.00179	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—sarcoma	0.000375	0.00179	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—sarcoma	0.000368	0.00176	CcSEcCtD
Norethindrone—Tension—Epirubicin—sarcoma	0.000366	0.00175	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—sarcoma	0.000362	0.00173	CcSEcCtD
Norethindrone—Dizziness—Etoposide—sarcoma	0.000359	0.00172	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—sarcoma	0.000358	0.00171	CcSEcCtD
Norethindrone—ALB—testis—sarcoma	0.000353	0.0187	CbGeAlD
Norethindrone—Alopecia—Doxorubicin—sarcoma	0.00035	0.00167	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—sarcoma	0.000347	0.00166	CcSEcCtD
Norethindrone—Vomiting—Etoposide—sarcoma	0.000345	0.00165	CcSEcCtD
Norethindrone—Rash—Etoposide—sarcoma	0.000342	0.00164	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—sarcoma	0.000342	0.00163	CcSEcCtD
Norethindrone—Headache—Etoposide—sarcoma	0.00034	0.00163	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—sarcoma	0.00034	0.00163	CcSEcCtD
Norethindrone—Tension—Doxorubicin—sarcoma	0.000339	0.00162	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—sarcoma	0.000335	0.0016	CcSEcCtD
Norethindrone—ALB—liver—sarcoma	0.000333	0.0177	CbGeAlD
Norethindrone—Convulsion—Epirubicin—sarcoma	0.000323	0.00154	CcSEcCtD
Norethindrone—Nausea—Etoposide—sarcoma	0.000323	0.00154	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000315	0.00151	CcSEcCtD
Norethindrone—CYP3A4—hematopoietic system—sarcoma	0.000306	0.0162	CbGeAlD
Norethindrone—Anaphylactic shock—Epirubicin—sarcoma	0.000304	0.00145	CcSEcCtD
Norethindrone—Oedema—Epirubicin—sarcoma	0.000304	0.00145	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—sarcoma	0.000299	0.00143	CcSEcCtD
Norethindrone—Skin disorder—Epirubicin—sarcoma	0.000296	0.00141	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000292	0.00139	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—sarcoma	0.000282	0.00135	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—sarcoma	0.000282	0.00135	CcSEcCtD
Norethindrone—PGR—lymph node—sarcoma	0.000279	0.0148	CbGeAlD
Norethindrone—Insomnia—Epirubicin—sarcoma	0.000275	0.00132	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—sarcoma	0.000274	0.00131	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—sarcoma	0.000271	0.00129	CcSEcCtD
Norethindrone—CYP2C19—liver—sarcoma	0.000268	0.0142	CbGeAlD
Norethindrone—Dyspepsia—Epirubicin—sarcoma	0.000268	0.00128	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Epirubicin—sarcoma	0.000263	0.00126	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—sarcoma	0.000263	0.00125	CcSEcCtD
Norethindrone—ALB—lymph node—sarcoma	0.000256	0.0136	CbGeAlD
Norethindrone—Insomnia—Doxorubicin—sarcoma	0.000255	0.00122	CcSEcCtD
Norethindrone—ABCB1—myometrium—sarcoma	0.000252	0.0134	CbGeAlD
Norethindrone—Somnolence—Doxorubicin—sarcoma	0.00025	0.0012	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—sarcoma	0.000249	0.00119	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—sarcoma	0.000248	0.00118	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000243	0.00116	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—sarcoma	0.000243	0.00116	CcSEcCtD
Norethindrone—ABCB1—embryo—sarcoma	0.000243	0.0129	CbGeAlD
Norethindrone—Urticaria—Epirubicin—sarcoma	0.000242	0.00116	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—sarcoma	0.000241	0.00115	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—sarcoma	0.00023	0.0011	CcSEcCtD
Norethindrone—ABCB1—seminal vesicle—sarcoma	0.000228	0.0121	CbGeAlD
Norethindrone—Hypersensitivity—Epirubicin—sarcoma	0.000224	0.00107	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—sarcoma	0.000224	0.00107	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—sarcoma	0.000223	0.00106	CcSEcCtD
Norethindrone—Asthenia—Epirubicin—sarcoma	0.000218	0.00104	CcSEcCtD
Norethindrone—ABCB1—hematopoietic system—sarcoma	0.000217	0.0115	CbGeAlD
Norethindrone—Pruritus—Epirubicin—sarcoma	0.000215	0.00103	CcSEcCtD
Norethindrone—CYP3A5—liver—sarcoma	0.000211	0.0112	CbGeAlD
Norethindrone—Hypersensitivity—Doxorubicin—sarcoma	0.000208	0.000992	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—sarcoma	0.000202	0.000966	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—sarcoma	0.000201	0.000962	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—sarcoma	0.000199	0.000952	CcSEcCtD
Norethindrone—Vomiting—Epirubicin—sarcoma	0.000194	0.000925	CcSEcCtD
Norethindrone—Rash—Epirubicin—sarcoma	0.000192	0.000917	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—sarcoma	0.000192	0.000916	CcSEcCtD
Norethindrone—Headache—Epirubicin—sarcoma	0.000191	0.000911	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—sarcoma	0.000186	0.00089	CcSEcCtD
Norethindrone—Nausea—Epirubicin—sarcoma	0.000181	0.000864	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—sarcoma	0.000179	0.000856	CcSEcCtD
Norethindrone—Rash—Doxorubicin—sarcoma	0.000178	0.000849	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—sarcoma	0.000177	0.000848	CcSEcCtD
Norethindrone—Headache—Doxorubicin—sarcoma	0.000176	0.000843	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—sarcoma	0.000167	0.0008	CcSEcCtD
Norethindrone—ABCB1—uterus—sarcoma	0.000164	0.00868	CbGeAlD
Norethindrone—CYP3A4—liver—sarcoma	0.000159	0.00841	CbGeAlD
Norethindrone—ABCB1—lymphoid tissue—sarcoma	0.000153	0.00809	CbGeAlD
Norethindrone—ABCB1—bone marrow—sarcoma	0.000139	0.00737	CbGeAlD
Norethindrone—ABCB1—testis—sarcoma	0.000119	0.0063	CbGeAlD
Norethindrone—ABCB1—liver—sarcoma	0.000112	0.00596	CbGeAlD
Norethindrone—ABCB1—lymph node—sarcoma	8.61e-05	0.00457	CbGeAlD
